These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 27237768)

  • 1. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
    De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
    Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
    Kappos L; De Stefano N; Freedman MS; Cree BA; Radue EW; Sprenger T; Sormani MP; Smith T; Häring DA; Piani Meier D; Tomic D
    Mult Scler; 2016 Sep; 22(10):1297-305. PubMed ID: 26585439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
    Kappos L; Radue EW; Chin P; Ritter S; Tomic D; Lublin F
    J Neurol; 2016 Feb; 263(2):354-360. PubMed ID: 26645392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod effect on brain volume loss independently contributes to its effect on disability.
    Sormani MP; De Stefano N; Francis G; Sprenger T; Chin P; Radue EW; Kappos L
    Mult Scler; 2015 Jun; 21(7):916-24. PubMed ID: 25662353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.
    Barkhof F; de Jong R; Sfikas N; de Vera A; Francis G; Cohen J;
    Mult Scler; 2014 Nov; 20(13):1704-13. PubMed ID: 24812043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
    Filippi M; Pagani E; Turrini R; Bartezaghi M; Brescia Morra V; Borriello G; Torri Clerici V; Mirabella M; Pasquali L; Patti F; Totaro R; Gallo P; Rocca MA;
    J Neurol; 2024 Sep; 271(9):6181-6196. PubMed ID: 39073436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
    Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T
    Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study.
    Preziosa P; Storelli L; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
    Neurotherapeutics; 2021 Apr; 18(2):878-888. PubMed ID: 33483938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
    Kappos L; O'Connor P; Radue EW; Polman C; Hohlfeld R; Selmaj K; Ritter S; Schlosshauer R; von Rosenstiel P; Zhang-Auberson L; Francis G
    Neurology; 2015 Apr; 84(15):1582-91. PubMed ID: 25795646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
    Zivadinov R; Medin J; Khan N; Korn JR; Bergsland N; Dwyer MG; Chitnis T; Naismith RT; Alvarez E; Kinkel P; Cohan S; Hunter SF; Silva D; Weinstock-Guttman B;
    J Neuroimaging; 2018 Jul; 28(4):399-405. PubMed ID: 29749661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
    Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
    Derfuss T; Bergvall NK; Sfikas N; Tomic DL
    Curr Med Res Opin; 2015; 31(9):1687-91. PubMed ID: 26121423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.
    Jeffery DR; Di Cantogno EV; Ritter S; Meier DP; Radue EW; Camu W
    J Neurol; 2016 Feb; 263(2):299-305. PubMed ID: 26568562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
    Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
    Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.